Issuu on Google+

Consolidated Investment Analysis for General Electric Co.

Berkshire Hathaway (NYSE: BRK/A) Company Description General Electric Company (GE) is a diversified technology, media and financial services company. Its products and services include aircraft engines, power generation, water processing, security technology, medical imaging, business and consumer financing, media content and industrial products. As of December 31, 2008, GE operated in five segments: Energy Infrastructure, Technology Infrastructure, NBC Universal, Capital Finance and Consumer & Industrial. In January 2009, the Company acquired Interbanca S.p.A., an Italian corporate bank. In April 2008, Oil & Gas completed the acquisition of the Hydril Pressure Controls business from Tenaris. In September 2008, the Company announced the sale of its Japanese consumer finance business to Shinsei Bank. During the year ended December 31, 2008, the Company acquired Whatman plc; Vital Signs, Inc.; Merrill Lynch Capital, and CitiCapital.In September 2009, the Company completed the acquisition of ScanWind. Share Statistics Symbol Current Price 52wk Range Avg Vol (3m)

GE 15.79 5.87- 17.52 74,752,700

EPS Market Cap 52wk Change P/E (ttm)

1.01 168.26B 42.25% 15.63

Financial Summary On January 22, 2010, General Electric Co reported 4th quarter 2009 earnings of 0.28 per share. This result exceeded the 0.26 consensus of the 13 analysts covering the company and under-performed last year's 4th quarter results by -45.10%. The next earnings announcement is expected on April 16, 2010. General Electric Co reported annual 2009 earnings of 1.03 per share on January 22, 2010. GE had 4th quarter 2009 revenues of 41.44bn. This bettered the 39.64bn consensus of the 8 analysts covering the company. This was 9.63% above the prior year's 4th quarter results. GE had revenues for the full year 2009 of 156.78k. This was -14.10% below the prior year's results.


Analyst Consensus Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 15 polled investment analysts. Against the General Electric Co company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

2

6

6

0

1

0

4 weeks ago

2

5

6

0

1

0

2 months ago

2

5

6

0

1

0

3 months ago

2

6

6

0

1

0

Last year

1

2

9

0

2

1

The 13 analysts offering 12 month price targets for General Electric Co (GE:NYQ) have a median target of 19.00, with a high estimate of 22.00 and a low estimate of 13.00. The median estimate represents a 20.33% increase from the last price of 15.79.

# of Estimates

Mean

High

Low

1 Year Ago

SALES (in millions)

Quarter Ending Mar-10

7

36,803.30

37,932.00

34,646.00

--

Quarter Ending Jun-10

7

38,740.40

39,847.00

37,359.00

--

Year Ending Dec-10

10

155,048.00

162,576.00

147,500.00

173,091.00

Year Ending Dec-11

8

152,902.00

168,646.00

142,761.00

176,185.00

Quarter Ending Mar-10

10

0.17

0.28

0.12

0.26

Quarter Ending Jun-10

8

0.25

0.27

0.22

0.24

Year Ending Dec-10

15

1.00

1.10

0.85

1.29

Year Ending Dec-11

13

1.18

1.35

0.90

1.48

LT Growth Rate (%)

6

9.70

17.20

5.00

9.00

Earnings (per share)


Technical Analysis Chart

Insider Trading Activity

Insider Purchases - Last 6 Months Shares Purchases Sales Net Shares Purchased (Sold) Total Insider Shares Held % Net Shares Purchased (Sold)

Trans 13,000

1

N/A

0

13,000

1

2.77M

N/A

0.5%

N/A

Net Institutional Purchases - Prior Qtr to Latest Qtr Shares Net Shares Purchased (Sold) % Change in Institutional Shares Held

(52,487,000) (1.0%)


Comparative Analysis

DIRECT COMPETITOR COMPARISON

GE

C

PHG

SI

Industry

Market Cap:

168.26B

91.72B

26.85B

74.05B

236.66M

Employ ees:

300,000

265,000

115,924

405,000

105

Qtrly Rev Growth (yoy):

-10.30%

N/A

-4.70%

-8.90%

13.90%

Revenue (ttm):

156.78B

51.63B

N/A

N/A

5.07B

7.12%

N/A

34.84%

27.02%

33.25%

23.87B

N/A

N/A

N/A

266.47M

7.12%

4.24%

N/A

N/A

6.91%

10.92B

-7.51B

N/A

N/A

N/A

EPS (ttm):

1.010

-0.688

N/A

N/A

N/A

P/E (ttm):

15.63

N/A

N/A

N/A

16.33

PEG (5 yr expected):

1.77

N/A

1.06

0.36

1.41

P/S (ttm):

1.09

1.75

N/A

N/A

1.15

Gross Margin (ttm): EBITDA (ttm): Oper Margins (ttm): Net Income (ttm):


Consolidated Investment Analysis for Caterpillar Inc. Caterpillar Inc. (NYSE: CAT) Company Description Caterpillar Inc. (Caterpillar) operates in three principal lines of business: Machinery, Engines and Financial Products. Machinery deals with the design, manufacture, marketing and sales of construction, mining and forestry machinery. Engines business deals with the design, manufacture, marketing and sales of engines. Financial Products, consists primarily of Caterpillar Financial Services Corporation (Cat Financial), Caterpillar Insurance Holdings, Inc. (Cat Insurance), Caterpillar Power Ventures Corporation (Cat Power Ventures) and their respective subsidiaries. In April 2008, Satyam Computer Services Limited acquired Caterpillar's market research and customer analytics operations. In April 2008, Caterpillar expanded its Global Mining business through the acquisition of Lovat Inc. (Lovat), a global manufacturer of tunnel boring machines used in the construction of metro, railway, road, sewer, water main, penstock, mine access, high voltage cable and telecommunications tunnels. Share Statistics Symbol CAT Current Price 51.75 52wk Range 21.71- 64.42 Avg Vol (3m) 8,412,410

EPS Market Cap 52wk Change P/E (ttm)

1.43 32.30B 55.50% 36.19

Financial Summary On January 27, 2010, Caterpillar Inc reported 4th quarter 2009 earnings of 0.41 per share. This result exceeded the 0.29 consensus of the 20 analysts covering the company and under-performed last year's 4th quarter results by -62.04%. The next earnings announcement is expected on April 23, 2010. Caterpillar Inc reported annual 2009 earnings of 2.18 per share on January 27, 2010. CAT had 4th quarter 2009 revenues of 7.19bn. This missed the 7.54bn consensus estimate of the 11 analysts following the company. This was 9.27% above the prior year's 4th quarter results. CAT had revenues for the full year 2009 of 29.54k. This was -38.51% below the prior year's results.


Analyst Consensus Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 21 polled investment analysts. Against the Caterpillar Inc company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

4

3

12

1

1

0

4 weeks ago

3

3

12

1

2

0

2 months ago

3

3

12

1

2

0

3 months ago

3

3

12

1

2

0

Last year

4

0

12

2

0

0

The 15 analysts offering 12 month price targets for Caterpillar Inc (CAT:NYQ) have a median target of 62.00, with a high estimate of 70.00 and a low estimate of 50.00. The median estimate represents a 19.81% increase from the last price of 51.75.

# of Estimates

Mean

High

Low

1 Year Ago

SALES (in millions)

Quarter Ending Mar-10

12

8,901.47

9,943.00

8,025.00

8,225.66

Quarter Ending Jun-10

12

8,930.23

9,474.33

8,266.00

9,832.06

Year Ending Dec-10

15

36,903.90

37,987.00

35,837.40

37,633.70

Year Ending Dec-11

15

41,947.70

43,719.70

40,059.00

38,477.80

Quarter Ending Mar-10

16

0.41

0.66

0.21

0.51

Quarter Ending Jun-10

16

0.66

1.00

0.42

0.75

Year Ending Dec-10

21

2.71

3.50

2.15

2.58

Year Ending Dec-11

20

4.02

4.85

3.50

2.45

LT Growth Rate (%)

4

36.50

120.00

5.00

10.60

Earnings (per share)


Technical Analysis Chart

Insider Trading Activity

Insider Purchases - Last 6 Months Shares Purchases Sales Net Shares Purchased (Sold) Total Insider Shares Held % Net Shares Purchased (Sold)

Trans N/A

0

120,300

7

(120,300)

7

87.53M

N/A

(0.1%)

N/A

Net Institutional Purchases - Prior Qtr to Latest Qtr Shares Net Shares Purchased (Sold) % Change in Institutional Shares Held

(15,318,500) (4.6%)


Competitive Comparison DIRECT COMPETITOR COMPARISON

CAT

CNH

KMTUY.PK

VOLVY.PK

Industry

Market Cap:

32.30B

5.38B

N/A

N/A

1.42B

Employ ees:

93,813

N/A

N/A

N/A

9.50K

-38.90%

-10.90%

N/A

N/A

12.20%

Revenue (ttm):

32.40B

13.76B

N/A

N/A

2.73B

Gross Margin (ttm):

23.04%

21.06%

N/A

N/A

21.29%

EBITDA (ttm):

3.62B

1.41B

N/A

N/A

60.10M

Oper Margins (ttm):

3.96%

7.37%

N/A

N/A

3.81%

895.00M

-190.00M

N/A

N/A

N/A

EPS (ttm):

1.430

-0.800

N/A

N/A

0.03

P/E (ttm):

36.19

N/A

N/A

N/A

24.21

PEG (5 yr expected):

1.36

1.82

3.23

7.99

1.82

P/S (ttm):

0.99

0.40

N/A

N/A

0.57

Qtrly Rev Growth (yoy):

Net Income (ttm):


Consolidated Investment Analysis for CVS Pharmaceuticals CVS Pharmaceuticals (NSYE: CVS) Company Description CVS Caremark Corporation (CVS Caremark) is a provider of prescriptions and related healthcare services in the United States. It is a pharmacy services company and drives value for its customers through its approximately 6,900 CVS/pharmacy and Longs Drug retail stores; CVS Caremark's pharmacy benefit management, mail order and specialty pharmacy division, Caremark Pharmacy Services; its retail-based health clinic subsidiary, MinuteClinic, and Its online pharmacy, CVS.com. The Company operates in two business segments: Pharmacy Services and Retail Pharmacy. October 20, 2008, CVS Caremark acquired Longs Drug Stores Corporation, which includes 529 retail drug stores (the Longs Drug Stores) and RxAmerica LLC (RxAmerica), which provides pharmacy benefit management services, and certain other related assets. Share Statistics Symbol CVS Current Price 31.07 52wk Range 23.74- 38.27 Avg Vol (3m) 17,649,100

EPS Market Cap 52wk Change P/E (ttm)

2.46 43.83B 6.99% 12.64

Financial Summary On November 05, 2009, CVS Caremark Corp reported 3rd quarter 2009 earnings of 0.65 per share. The next earnings announcement is expected on February 08, 2010. CVS Caremark Corp reported annual 2008 earnings of 2.18 per share on February 19, 2009. The next earnings announcement from CVS Caremark Corp is expected the week of February 08, 2010. CVS had 3rd quarter 2009 revenues of 24.64bn. This bettered the 24.63bn consensus of the 15 analysts covering the company. This was -0.92% below the prior year's 3rd quarter results. CVS had revenues for the full year 2008 of 87.47k. This was 14.60% above the prior year's results.


Analyst Consensus Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 20 polled investment analysts. Against the CVS Caremark Corp company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

10

7

3

0

0

0

4 weeks ago

10

7

4

0

0

0

2 months ago

10

7

4

0

0

0

3 months ago

10

7

4

0

0

0

Last year

8

6

2

0

0

0

The 16 analysts offering 12 month price targets for CVS Caremark Corp (CVS:NYQ) have a median target of 37.50, with a high estimate of 42.00 and a low estimate of 33.00. The median estimate represents a 20.70% increase from the last price of 31.07.

# of Estimates

Mean

High

Low

1 Year Ago

SALES (in millions)

Quarter Ending Mar-10

6

24,182.80

24,701.60

23,464.00

24,995.10

Quarter Ending Jun-10

6

24,922.90

25,491.00

24,260.00

25,380.30

17

99,998.30

104,125.00

91,587.00

102,933.00

Quarter Ending Mar-10

10

0.61

0.66

0.55

0.59

Quarter Ending Jun-10

10

0.68

0.71

0.66

0.67

Year Ending Dec-10

18

2.76

2.85

2.53

2.82

LT Growth Rate (%)

11

13.12

16.00

4.00

13.43

Year Ending Dec-10

Earnings (per share)


Technical Analysis Chart

Insider Purchases - Last 6 Months Shares Purchases Sales Net Shares Purchased (Sold) Total Insider Shares Held % Net Shares Purchased (Sold)

Trans 63,483

3

1,618,400

9

(1,554,917)

12

2.17M

N/A

(41.7%)

N/A

Net Institutional Purchases - Prior Qtr to Latest Qtr Shares Net Shares Purchased (Sold) % Change in Institutional Shares Held

(69,996,000) (6.2%)


Competitive Comparison DIRECT COMPETITOR COMPARISON

CVS

RAD

WAG

WMT

Industry

Market Cap:

43.83B

1.16B

32.82B

203.65B

1.16B

Employ ees:

215,000

57,680

166,000

2,100,000

57.68K

Qtrly Rev Growth (yoy):

18.10%

-1.80%

9.50%

1.10%

38.90%

Revenue (ttm):

97.05B

25.91B

64.75B

404.54B

25.91B

Gross Margin (ttm):

20.65%

26.52%

27.97%

25.00%

27.97%

EBITDA (ttm):

7.68B

674.55M

4.62B

30.36B

4.62B

Oper Margins (ttm):

6.49%

0.48%

5.65%

5.79%

4.25%

Net Income (ttm):

3.61B

-2.60B

2.09B

13.52B

N/A

EPS (ttm):

2.459

-2.972

2.104

3.454

0.87

P/E (ttm):

12.64

N/A

15.83

15.47

15.83

PEG (5 yr expected):

0.98

N/A

1.02

1.25

0.98

P/S (ttm):

0.45

0.05

0.51

0.50

0.45


Consolidated Investment Analysis for Bristol Myers Squibb Co. Bristol- Myers Squibb Co. (NYSE: BMY) Company Description Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children's nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline plc. Share Statistics Symbol Current Price 52wk Range Avg Vol (3m)

BMY 23.97 17.23- 26.62 25,942,800

EPS Market Cap 52wk Change P/E (ttm)

5.36 47.48B 3.90% 4.48

Financial Summary On January 28, 2010, Bristol-Myers Squibb Co reported 4th quarter 2009 earnings of 0.47 per share. This result exceeded the 0.42 consensus of the 12 analysts covering the company and exceeded last year's 4th quarter results by 2.17%. The next earnings announcement is expected on April 26, 2010. Bristol-Myers Squibb Co reported annual 2009 earnings of 1.85 per share on January 28, 2010. BMY had 4th quarter 2009 revenues of 5.03bn. This bettered the 4.95bn consensus of the 8 analysts covering the company. This was -8.27% below the prior year's 4th quarter results. BMY had revenues for the full year 2009 of 18.81k. This was -8.69% below the prior year's results.


Analyst Consensus Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 19 polled investment analysts. Against the Bristol-Myers Squibb Co company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

3

1

13

0

2

0

4 weeks ago

3

1

13

0

1

0

2 months ago

3

1

11

0

1

0

3 months ago

4

1

11

0

1

0

Last year

5

2

9

0

0

0

The 13 analysts offering 12 month price targets for Bristol-Myers Squibb Co (BMY:NYQ) have a median target of 26.00, with a high estimate of 28.00 and a low estimate of 20.80. The median estimate represents a 8.47% increase from the last price of 23.97.

# of Estimates

Mean

High

Low

1 Year Ago

SALES (in millions)

Quarter Ending Mar-10

11

4,713.01

4,900.00

4,550.00

--

Quarter Ending Jun-10

11

4,945.43

5,000.00

4,873.00

--

Year Ending Dec-10

15

19,967.50

20,325.00

19,602.90

23,265.30

Year Ending Dec-11

14

20,995.00

21,680.00

19,955.00

24,578.30

Quarter Ending Mar-10

13

0.53

0.57

0.49

--

Quarter Ending Jun-10

11

0.57

0.59

0.54

--

Year Ending Dec-10

17

2.21

2.30

2.14

2.23

Year Ending Dec-11

16

2.45

2.62

2.15

2.53

LT Growth Rate (%)

7

4.96

12.50

-2.00

9.59

Earnings (per share)


Technical Analysis Chart

Insider Trading Activity

Insider Purchases - Last 6 Months Shares

Trans

Purchases

N/A

0

Sales

N/A

0

N/A

0

257.53K

N/A

0.0%

N/A

Net Shares Purchased (Sold) Total Insider Shares Held % Net Shares Purchased (Sold) Net Institutional Purchases - Prior Qtr to Latest Qtr

Shares Net Shares Purchased (Sold) % Change in Institutional Shares Held

(58,624,700) (3.7%)


Comparative Analysis

DIRECT COMPETITOR COMPARISON

BMY

MRK

NVS

PFE

Industry

Market Cap:

47.48B

77.47B

121.30B

144.93B

104.64M

Employ ees:

N/A

55,200

99,000

81,800

86

Qtrly Rev Growth (yoy):

-4.10%

1.80%

2.40%

-2.90%

14.60%

Revenue (ttm):

18.81B

23.37B

42.31B

45.82B

31.21M

Gross Margin (ttm):

73.37%

76.36%

72.61%

86.61%

72.61%

5.86B

7.81B

11.24B

21.31B

-1.59M

27.55%

26.63%

21.50%

37.42%

7.67%

Net Income (ttm):

3.24B

8.05B

7.59B

8.09B

N/A

EPS (ttm):

5.356

3.808

3.34

1.204

N/A

P/E (ttm):

4.48

9.65

15.99

14.92

12.60

PEG (5 yr expected):

3.58

2.45

2.97

5.39

2.19

P/S (ttm):

2.53

3.35

2.90

3.18

3.32

EBITDA (ttm): Oper Margins (ttm):


Consolidated Investment Analysis for Eli Lilly and Co. Eli Lilly and Co. (NYSE: LLY) Company Description Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through owned or leased facilities in the United States, Puerto Rico and 25 other countries. Eli Lilly and Company's products are sold in approximately 135 countries. The Company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its principal products include Neurosciences products, Endocrinology products, Oncology products, Cardiovascular products, Animal health products and Other pharmaceuticals. On August 20, 2008, the Company acquired SGX Pharmaceuticals, Inc. (SGX). On November 24, 2008, the Company acquired ImClone Systems Inc. (ImClone), a biopharmaceutical company focused on advancing oncology care. Share Statistics Symbol Current Price 52wk Range Avg Vol (3m)

LLY 34.52 27.21- 38.74 6,841,680

EPS Market Cap 52wk Change P/E (ttm)

3.94 39.66B -9.59% 8.76

Financial Summary On January 28, 2010, Eli Lilly and Co reported 4th quarter 2009 earnings of 0.91 per share. The next earnings announcement is expected on April 19, 2010. Eli Lilly and Co reported annual 2009 earnings of 4.42 per share on January 28, 2010. LLY had 4th quarter 2009 revenues of 5.93bn. This bettered the 5.68bn consensus of the 12 analysts covering the company. This was 6.69% above the prior year's 4th quarter results. LLY had revenues for the full year 2009 of 21.84k. This was 7.34% above the prior year's results.


Analyst Consensus Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 21 polled investment analysts. Against the Eli Lilly and Co company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

2

0

12

5

2

0

4 weeks ago

2

0

12

5

1

0

2 months ago

2

0

11

5

1

0

3 months ago

2

1

10

5

1

0

Last year

2

0

14

1

1

0

The 14 analysts offering 12 month price targets for Eli Lilly and Co (LLY:NYQ) have a median target of 36.00, with a high estimate of 43.00 and a low estimate of 32.70. The median estimate represents a 4.29% increase from the last price of 34.52.

# of Estimates

Mean

High

Low

1 Year Ago

SALES (in millions)

Quarter Ending Mar-10

8

5,505.36

5,704.00

5,295.00

--

Quarter Ending Jun-10

8

5,733.89

5,900.00

5,595.00

--

Year Ending Dec-10

15

23,361.40

23,900.00

22,555.00

22,590.10

Year Ending Dec-11

14

23,381.70

24,442.40

21,840.00

23,095.40

Quarter Ending Mar-10

11

1.12

1.26

1.01

1.09

Quarter Ending Jun-10

9

1.17

1.22

1.13

1.11

Year Ending Dec-10

19

4.75

4.98

4.60

4.47

Year Ending Dec-11

18

4.73

5.17

3.68

4.57

LT Growth Rate (%)

5

1.18

12.50

-10.70

6.80

Earnings (per share)


Technical Analysis Chart

Insider Trading Activity

Insider Purchases - Last 6 Months Shares Purchases Sales Net Shares Purchased (Sold) Total Insider Shares Held % Net Shares Purchased (Sold)

Trans N/A

0

2,673

1

(2,673)

1

1.76M

N/A

(0.2%)

N/A

Net Institutional Purchases - Prior Qtr to Latest Qtr Shares Net Shares Purchased (Sold) % Change in Institutional Shares Held

(9,464,080) (1.1%)


Competitive Comparison DIRECT COMPETITOR COMPARISON

LLY

GSK

NVO

PFE

Industry

Market Cap:

39.66B

96.48B

41.38B

144.93B

104.64M

Employ ees:

40,360

99,003

28,497

81,800

86

Qtrly Rev Growth (yoy):

13.90%

14.90%

11.30%

-2.90%

14.60%

Revenue (ttm):

21.84B

42.86B

9.33B

45.82B

31.21M

Gross Margin (ttm):

80.55%

76.27%

79.57%

86.61%

72.61%

7.60B

16.90B

3.22B

21.31B

-1.59M

29.17%

34.30%

29.92%

37.42%

7.67%

Net Income (ttm):

4.33B

7.70B

1.99B

8.09B

N/A

EPS (ttm):

3.941

3.02

3.26

1.204

N/A

P/E (ttm):

8.76

12.60

21.29

14.92

12.60

PEG (5 yr expected):

N/A

2.29

1.28

5.39

2.19

P/S (ttm):

1.82

2.28

4.47

3.18

3.32

EBITDA (ttm): Oper Margins (ttm):


Consolidated Investment Analysis for Deere & Co. Deere & Co. (NYSE: DE) Company Description Deere & Company, together with its subsidiaries (John Deere) operates in three business segments: agriculture and turf segment, construction and forestry segment, and credit segment. The agriculture and turf segment, created by combining the former agricultural equipment and commercial and consumer equipment segments, manufactures and distributes a range of farm and turf equipment, and related service parts. The construction and forestry segment manufactures, distributes to dealers and sells at retail machines and service parts used in construction, earthmoving, material handling and timber harvesting. The credit segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. In addition, it provides wholesale financing to dealers of the foregoing equipment, provides operating loans, finances retail revolving charge accounts, offers crop risk mitigation products and invests in wind energy generation. Share Statistics Symbol Current Price 52wk Range Avg Vol (3m)

DE 49.82 24.51- 60.16 4,970,460

EPS Market Cap 52wk Change P/E (ttm)

2.06 21.06B 19.16% 24.21

Financial Summary On November 25, 2009, Deere & Co reported 4th quarter 2009 earnings of 0.23 per share. This result exceeded the 0.02 consensus of the 18 analysts covering the company and under-performed last year's 4th quarter results by -74.16%. The next earnings announcement is expected on February 17, 2010. Deere & Co reported annual 2009 earnings of 2.84 per share on November 25, 2009. The next earnings announcement from Deere & Co is expected the week of November 24, 2010. DE had 4th quarter 2009 revenues of 4.73bn. This bettered the 4.42bn consensus of the 11 analysts covering the company. This was -10.54% below the prior year's 4th quarter results. DE had revenues for the full year 2009 of 20.76k. This was -19.56% below the prior year's results.


Analyst Consensus Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 21 polled investment analysts. Against the Deere & Co company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

6

3

12

0

0

0

4 weeks ago

6

3

11

0

0

0

2 months ago

6

3

11

0

0

0

3 months ago

5

2

12

1

0

0

Last year

4

2

8

0

0

1

The 14 analysts offering 12 month price targets for Deere & Co (DE:NYQ) have a median target of 60.00, with a high estimate of 64.00 and a low estimate of 51.00. The median estimate represents a 20.43% increase from the last price of 49.82.

# of Estimates

Mean

High

Low

1 Year Ago

SALES (in millions)

Quarter Ending Apr-10

12

6,108.58

6,356.20

5,831.00

5,636.00

Quarter Ending Jul-10

12

5,540.13

6,125.00

5,247.70

5,475.00

Year Ending Oct-10

15

20,949.40

23,261.00

20,093.00

24,686.80

Year Ending Oct-11

15

22,861.80

24,374.00

21,073.00

26,445.60

Quarter Ending Apr-10

17

0.91

1.18

0.70

0.75

Quarter Ending Jul-10

17

0.76

1.14

0.58

0.59

Year Ending Oct-10

22

2.52

3.13

2.00

4.15

Year Ending Oct-11

20

3.56

4.25

2.79

4.42

LT Growth Rate (%)

5

9.20

14.00

5.00

10.00

Earnings (per share)


Technical Analysis Chart

Insider Trading Activity

Insider Purchases - Last 6 Months Shares Purchases Sales Net Shares Purchased (Sold) Total Insider Shares Held % Net Shares Purchased (Sold)

Trans 1,000

1

55,000

6

(54,000)

7

532.52K

N/A

(9.2%)

N/A

Net Institutional Purchases - Prior Qtr to Latest Qtr Shares Net Shares Purchased (Sold) % Change in Institutional Shares Held

(24,441,900) (8.6%)


Competitive Comparison DIRECT COMPETITOR COMPARISON

DE

CAT

CNH

KUB

Industry

Market Cap:

21.06B

32.30B

5.38B

11.32B

1.42B

Employ ees:

51,300

93,813

N/A

25,173

9.50K

-27.90%

-38.90%

-10.90%

-19.70%

12.20%

Revenue (ttm):

23.11B

32.40B

13.76B

10.99B

2.73B

Gross Margin (ttm):

26.85%

23.04%

21.06%

26.13%

21.29%

EBITDA (ttm):

2.73B

3.62B

1.41B

1.11B

60.10M

Oper Margins (ttm):

8.04%

3.96%

7.37%

6.98%

3.81%

873.50M

895.00M

-190.00M

355.00M

N/A

EPS (ttm):

2.058

1.430

-0.800

1.40

0.03

P/E (ttm):

24.21

36.19

N/A

31.79

24.21

PEG (5 yr expected):

1.99

1.36

1.82

N/A

1.82

P/S (ttm):

0.91

0.99

0.40

1.03

0.57

Qtrly Rev Growth (yoy):

Net Income (ttm):


Report Disclaimer DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS. We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing. This report is a service of Seo Freisin, Inc., a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclosed on both, this newsletter, and on our website in accordance with section 17(b) of the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. ChartPoppers.com is a Web site wholly-owned by Seo Freisin, Inc. Seo Freisin, Inc., has not been compensated for any of the Companies mentioned in this report, we also do not own any shares in the companies discussed in this report. Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are


cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org


GE, CAT, CVS, BMY, LLY, DE